Frans Van de Werf

3.2k total citations · 1 hit paper
16 papers, 2.3k citations indexed

About

Frans Van de Werf is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Frans Van de Werf has authored 16 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Cardiology and Cardiovascular Medicine and 4 papers in Surgery. Recurrent topics in Frans Van de Werf's work include Diabetes Treatment and Management (10 papers), Diabetes Management and Research (5 papers) and Antiplatelet Therapy and Cardiovascular Diseases (3 papers). Frans Van de Werf is often cited by papers focused on Diabetes Treatment and Management (10 papers), Diabetes Management and Research (5 papers) and Antiplatelet Therapy and Cardiovascular Diseases (3 papers). Frans Van de Werf collaborates with scholars based in Belgium, United States and United Kingdom. Frans Van de Werf's co-authors include Rury R. Holman, Paul W. Armstrong, Jennifer B. Green, Eric D. Peterson, John B. Buse, Eberhard Standl, John M. Lachin, Darren K. McGuire, Jyotsna Garg and M. Angelyn Bethel and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Frans Van de Werf

13 papers receiving 2.2k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

2015 1.9k citations Jennifer B. Green, M. Angelyn Bethel et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frans Van de Werf Belgium	8	1.9k	733	666	611	313	16	2.3k
Robert Josse Canada	10	1.7k 0.9×	730 1.0×	665 1.0×	426 0.7×	426 1.4×	17	2.2k
Samuel S. Engel United States	5	1.7k 0.9×	654 0.9×	549 0.8×	430 0.7×	276 0.9×	6	1.9k
Alfonso T. Perez United States	7	2.8k 1.4×	1.3k 1.8×	882 1.3×	676 1.1×	464 1.5×	8	3.2k
Egon Pfarr Germany	12	1.5k 0.8×	497 0.7×	489 0.7×	421 0.7×	217 0.7×	20	1.8k
Sven Schnaidt Germany	13	1.5k 0.8×	517 0.7×	540 0.8×	622 1.0×	207 0.7×	22	1.9k
Sanjay Patel United Kingdom	21	1.9k 1.0×	788 1.1×	829 1.2×	178 0.3×	514 1.6×	67	2.3k
Gregory T. Golm United States	26	2.3k 1.2×	1.0k 1.4×	800 1.2×	139 0.2×	459 1.5×	52	2.5k
Mark Warren United States	14	1.8k 0.9×	745 1.0×	643 1.0×	192 0.3×	104 0.3×	32	2.0k
Richard E. Gilbert Australia	24	839 0.4×	579 0.8×	289 0.4×	681 1.1×	75 0.2×	44	2.2k
Ambady Ramachandran India	6	1.5k 0.8×	572 0.8×	448 0.7×	255 0.4×	32 0.1×	9	1.6k

Countries citing papers authored by Frans Van de Werf

Since Specialization

Citations

This map shows the geographic impact of Frans Van de Werf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frans Van de Werf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frans Van de Werf more than expected).

Fields of papers citing papers by Frans Van de Werf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frans Van de Werf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frans Van de Werf. The network helps show where Frans Van de Werf may publish in the future.

Co-authorship network of co-authors of Frans Van de Werf

This figure shows the co-authorship network connecting the top 25 collaborators of Frans Van de Werf. A scholar is included among the top collaborators of Frans Van de Werf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frans Van de Werf. Frans Van de Werf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Staessen, Jan A., Stefan Janssens, & Frans Van de Werf. (2021). Do clinical trial data suggest a role for SGLT2-inhibitors in primary prevention of heart failure and chronic kidney disease?. International Journal of Cardiology Cardiovascular Risk and Prevention. 10. 200100–200100. 1 indexed citations

Pencina, Michael, Jennifer B. Green, Keith D. Kaufman, et al.. (2021). Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. UNC Libraries.

Koglin, Joerg, Frans Van de Werf, Eberhard Standl, et al.. (2020). Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. UNC Libraries. 2 indexed citations

McAlister, Finlay A., Yinggan Zheng, Cynthia M. Westerhout, et al.. (2020). Association Between Glycated Haemoglobin Levels and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease: A Secondary Analysis of the TECOS Randomized Clinical Trial. European Journal of Heart Failure. 22(11). 2026–2034. 16 indexed citations

Reed, Shelby D., Yanhong Li, José Leal, et al.. (2018). Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obesity and Metabolism. 20(7). 1732–1739. 4 indexed citations

Alfredsson, Joakim, Jennifer B. Green, Susanna R. Stevens, et al.. (2018). Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. Diabetes Obesity and Metabolism. 20(10). 2379–2388. 25 indexed citations

Standl, Eberhard, Susanna R. Stevens, Paul W. Armstrong, et al.. (2018). Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. Diabetes Care. 41(3). 596–603. 49 indexed citations

Bethel, M. Angelyn, S. Engel, Eberhard Standl, et al.. (2016). Assessing the safety of sitagliptin in elderly participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetic Medicine. 33. 86–86. 1 indexed citations

McGuire, Darren K., Frans Van de Werf, Paul W. Armstrong, et al.. (2016). Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. JAMA Cardiology. 1(2). 126–126. 167 indexed citations

10.

Green, Jennifer B., M. Angelyn Bethel, Paul W. Armstrong, et al.. (2015). Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 373(3). 232–242. 1866 indexed citations breakdown →

11.

Harrington, RA, et al.. (2001). Diabetes doubles the risk of death among patients presenting with acute coronary syndromes: insights from SYMPHONY, a large international trial. Journal of the American College of Cardiology. 37(2). 1 indexed citations

12.

Werf, Frans Van de, Christopher P. Cannon, Carolyn H. McCabe, et al.. (1999). Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial. American Heart Journal. 137(5). 786–791. 111 indexed citations

13.

Werf, Frans Van de. (1996). Implications of the GUSTO Trial for Thrombolytic Therapy. Drugs. 52(3). 307–312. 1 indexed citations

14.

Ml, Simoons, et al.. (1994). Compensatory Hyperkinesis : The Ejection Fraction 'Equalizer' after MI. Circulation. 90(4).

15.

Somers, Yves, et al.. (1993). Combined thromboxane A2synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase. Journal of the American College of Cardiology. 21(5). 1269–1279. 10 indexed citations

16.

Werf, Frans Van de. (1988). Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trial. Journal of the American College of Cardiology. 12(6). A14–A19. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact